The DOI matches its Crossref record; 86 of the 87 references it cites were found in a registry or an index.
Ketamine treatment for depression: a review
Open accessAbstract
This manuscript reviews the clinical evidence regarding single-dose intravenous (IV) administration of the novel glutamatergic modulator racemic ( R,S )-ketamine (hereafter referred to as ketamine) as well as its S -enantiomer, intranasal esketamine, for the treatment of major depressive disorder (MDD). Initial studies found that a single subanesthetic-dose IV ketamine infusion rapidly (within one day) improved depressive symptoms in individuals with MDD and bipolar depression, with antidepressant effects lasting three to seven days. In 2019, esketamine received FDA approval as an adjunctive treatment for treatment-resistant depression (TRD) in adults. Esketamine was approved under a risk evaluation and mitigation strategy (REMS) that requires administration under medical supervision. Both ketamine and esketamine are currently viable treatment options for TRD that offer the possibility of rapid symptom improvement. The manuscript also reviews ketamine’s use in other psychiatric diagnoses—including suicidality, obsessive–compulsive disorder, post-traumatic stress disorder, substance abuse, and social anxiety disorder—and its potential adverse effects. Despite limited data, side effects for antidepressant-dose ketamine—including dissociative symptoms, hypertension, and confusion/agitation—appear to be tolerable and limited to around the time of treatment. Relatively little is known about ketamine’s longer-term effects, including increased risks of abuse and/or dependence. Attempts to prolong ketamine’s effects with combined therapy or a repeat-dose strategy are also reviewed, as are current guidelines for its clinical use. In addition to presenting a novel and valuable treatment option, studying ketamine also has the potential to transform our understanding of the mechanisms underlying mood disorders and the development of novel therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Proposed mechanisms of action of ketamine and esketamine. Ketamine’s (and esketamine’s) actions at the glutamate receptor that may mediate antidepressant effects include: (1) blocking the N-methyl-D-aspartate (NMDA) receptor at the gamma aminobutyric acid (GABA)-ergic inhibitory interneuron, leading to disinhibition of presynaptic neurons and resulting in increased glutamate release into the synapse (disinhibition hypothesis). Other downstream molecular and cellular pathways have also been investigated to better understand ketamine’s rapid acting antidepressant properties and its effects on promoting neuroplasticity. These include: (2) inhibition of synaptic and (3) extra-synaptic NMDA receptors leading to intracellular pathways promoting neuroplasticity; (4) inhibitory effects of the NMDA receptor in the lateral habenula (LHb) neurons; (5) α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor activation from increased synaptic glutamate release and/or ketamine metabolites (e.g., (2R, 6R)-hydroxynorketamine (HNK)); and (6) presynaptic metabotropic glutamate receptor (mGluR) (group II) antagonism leading to enhanced glutamate release and subsequent AMPA receptor activation, leading to downstream molecular and cellular pathways promoting neuroplasticity. Adapted with permission from [21].](https://figures.cochat.ai/paper-figures/7c41b72917034884b6c46d43bd84589f/ketamine-treatment-for-depression-a-review-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A key mechanism of ketamine and esketamine may be the upregulation of BDNF levels [18,19], which plays a critical role in synaptic resilience and neuroplasticity [20].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, ketamine impacts neuroplasticity, including through BDNF, in both a rapid and sustained manner [18,19,77]”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine and its S-enantiomer, esketamine, exert both rapid and sustained antidepressant effects through activation of glutamate-related pathways, with neurotrophic effects involving BDNF, as demonstrated in experimental studies.”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine, a non-competitive antagonist of the NMDA receptor, has attracted considerable interest for its ability to produce rapid and sustained antidepressant effects, particularly in individuals with treatment-resistant depression [18].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The rapid onset of these effects, often evident within hours, and their persistence for weeks after a single dose suggest that ketamine’s action involves more complex processes than simple NMDA receptor blockade, particularly those related to synaptic plasticity and neurotrophic signaling, including BDNF pathways [18,19].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [18]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
The National Center for Biotechnology Information
Benson, D., Boguski, M., Lipman, D. J., & Ostell, J. (1990) · Genomics · doi:10.1016/0888-7543(90)90583-g · Cited by 5,126
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“Compared to saline infusion, ketamine significantly improved depressive symptoms within 72 h [22].”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609 · cited 3×
“Notably, animal studies found that arketamine has more potent, longer-lasting antidepressant effects than either ketamine or esketamine with fewer behavioral side effects and lower abuse potential [11].”
BackgroundKetamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260 · cited 1×
“Early work by Skolnick and colleagues implicated the glutamatergic system in depression [7], and research over the past three decades further implicated the NMDA receptor in modulating the molecular and cellular processes important for synaptogenesis and neuroplasticity [8].”
BackgroundSelf-citationMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127 · cited 1×
“AMPA receptor activation in particular has been shown to modulate downstream factors, such as enhancing brain-derived neurotrophic factor (BDNF) release, which activates the tropomyosin receptor kinase B (TrkB) receptor and, subsequently, mammalian target of rapamycin complex 1 (mTORC1) [16].”
BackgroundKetamine blocks bursting in the lateral habenula to rapidly relieve depression
Yang, Y., Cui, Y., Sang, K., Dong, Y., Ni, Z., Ma, S., & Hu, H. (2018) · Nature · doi:10.1038/nature25509 · Cited by 1,036 · cited 1×
“A recent study demonstrated that blockade of NMDA-dependent burst activity in the lateral habenula (LHb) mediated antidepressantlike effects in animals [9], and neurochemical and functional imaging studies have also corroborated that ketamine treatment partly reverses the glutamatergic and gamma aminobutyric acid (GAB…”
BackgroundDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 1×
“In two randomized, placebo-controlled, crossover studies (n = 15 and n = 18), ketamine significantly improved depressive symptoms compared to placebo; effects were observed within 40 min and lasted through three days post-infusion [30, 31].”
BackgroundSelf-citationPopova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · cited 1×
“The TRANSFORM-2 study was a four-week, randomized, placebo-controlled, double-blind Phase 3 clinical trial (n = 223) that included an antidepressant medication taper and randomization to either twice-weekly intranasal esketamine, flexibly dosed at 56 or 84 mg, or a placebo nasal spray, both administered in conjunction…”
MethodZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Self-citationDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785 · cited 1×
“Trullas and Skolnick were the first to propose that NMDA receptor pathways might be involved in behavioral changes resulting from inescapable stress [2], laying the ground work for exploring ketamine’s potential antidepressant effects.”
BackgroundMcIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Self-citationWilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696 · cited 1×
“85) up to one week post-treatment [46].”
Self-citationSafety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606 · cited 1×
“In the first, randomized, placebo-controlled, double-blind study (TRANSFORM-1), 346 participants with TRD were recruited to assess the efficacy of twice-weekly intranasal esketamine (either 56 or 84 mg) plus a newly-initiated oral antidepressant [33].”
MethodKetamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576 · cited 1×
“Guidelines published by JAMA Psychiatry [84] and, more recently, the American Journal of Psychiatry (AJP) [85] also underscore the strong evidence for ketamine’s antidepressant efficacy and provide detailed recommendations for its clinical use with necessary precautions to ensure patient safety.”
BackgroundSingh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525 · cited 1×
“Another double-blind, randomized, placebo-controlled study of twice weekly versus thrice weekly IV ketamine administered over four weeks similarly demonstrated the effectiveness of repeated infusions in maintaining antidepressant effect; no significant difference was seen between the different dosing frequencies [39].”
BackgroundAttenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519 · cited 1×
“The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor [11], metabotropic glutamate receptor (mGluR) [12, 13], and opioidergic [14] signaling pathways have all been implicated in ketamine’s antidepressant properties.”
BackgroundOchs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481 · cited 1×
“Another study (TRANSFORM-3) administered twice-weekly intranasal esketamine to 138 patients with TRD aged 65 years or older and found no significant difference in the primary endpoint of change in MADRS score after four weeks for those using intranasal esketamine (flexibly dosed at 28, 56, or 84 mg) plus a new oral an…”
BackgroundLener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468 · cited 2×
“A recent study demonstrated that blockade of NMDA-dependent burst activity in the lateral habenula (LHb) mediated antidepressantlike effects in animals [9], and neurochemical and functional imaging studies have also corroborated that ketamine treatment partly reverses the glutamatergic and gamma aminobutyric acid (GAB…”
BackgroundSelf-citationPhillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070834 · Cited by 418
Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa068 · Cited by 418 · cited 1×
“A recent study evaluated the efficacy of esketamine nasal spray (84 mg) administered twice a week versus placebo for four weeks in MDD patients with suicidal ideation in conjunction with standard care [43].”
BackgroundKetamine: Current applications in anesthesia, pain, and critical care
Kurdi, M., Theerth, K., & Deva, R. (2014) · Anesthesia: Essays and Researches · doi:10.4103/0259-1162.143110 · Cited by 392 · cited 1×
“Compared to anesthetic doses (typically 1–3 mg/kg) [75, 76], the sub-anesthetic dose of ketamine used to treat TRD is considerably lower (typically 0.”
BackgroundRandomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
Ketamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385 · cited 1×
“Racemic (R,S)-ketamine (hereafter referred to as ketamine), first synthesized in 1962, is a rapid-acting general anesthetic; it has been on the World Health Organization’s Essential Medications List since 1985 [1].”
BackgroundGlutamate-based antidepressants: 20 years on
Skolnick, P., Popik, P., & Trullas, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.002 · Cited by 380
McGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373
Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016) · Psychological Medicine · doi:10.1017/s0033291716000064 · Cited by 359 · cited 1×
“For instance, a meta-analysis of nine randomized, placebo-controlled studies found that ketamine had antidepressant effects that began approximately 40 min post-infusion, peaked approximately 24 h later, and lost superiority to placebo after 10–12 days [24].”
BackgroundSelf-citationPrice, R. B., Iosifescu, D. V., Murrough, J. W., Chang, L. C., Al Jurdi, R. K., Iqbal, S. Z., Soleimani, L., Charney, D. S., Foulkes, A. L., & Mathew, S. J. (2014) · Depression and Anxiety · doi:10.1002/da.22253 · Cited by 345 · cited 1×
“A single, subanesthetic-dose IV ketamine infusion was shown to rapidly and effectively reduce suicidal ideation in controlled trials of TRD patients [40, 44].”
BackgroundSkolnick, P., Layer, R., Popik, P., Nowak, G., Paul, I., & Trullas, R. (1996) · Pharmacopsychiatry · doi:10.1055/s-2007-979537 · Cited by 344 · cited 1×
“Early work by Skolnick and colleagues implicated the glutamatergic system in depression [7], and research over the past three decades further implicated the NMDA receptor in modulating the molecular and cellular processes important for synaptogenesis and neuroplasticity [8].”
BackgroundPharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01093-2 · Cited by 271 · cited 1×
“The variable action of ketamine’s enantiomers and respective metabolites on NMDA and AMPA receptors adds to the challenge of elucidating ketamine’s particular antidepressant effects [18], and additional downstream molecular and cellular pathways have been investigated to better understand ketamine’s rapid-acting antid…”
BackgroundSelf-citationChaki, S., Yoshikawa, R., Hirota, S., Shimazaki, T., Maeda, M., Kawashima, N., Yoshimizu, T., Yasuhara, A., Sakagami, K., Okuyama, S., et al. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.10.009 · Cited by 254 · cited 1×
“The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor [11], metabotropic glutamate receptor (mGluR) [12, 13], and opioidergic [14] signaling pathways have all been implicated in ketamine’s antidepressant properties.”
BackgroundKetamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00275-1 · Cited by 246
Feder, A., Costi, S., Rutter, S. B., Collins, A. B., Govindarajulu, U., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20050596 · Cited by 246 · cited 7×
“The primary endpoint was defined as change from baseline to two weeks in PTSD symptom severity, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).”
BackgroundInfluentialThe role of dissociation in ketamine’s antidepressant effects
Ballard, E. D., & Zarate, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-20190-4 · Cited by 220 · cited 1×
“However, these dissociative effects have not been found to be necessary for ketamine’s antidepressant effects [78, 79].”
BackgroundSelf-citationDore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1587556 · Cited by 217
Cognitive dysfunction in major depressive disorder
Knight, M. J., & Baune, B. T. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000378 · Cited by 207 · cited 1×
“Cognitive deficits in the domains of executive functioning, attention, memory, psychomotor speed, and cognitive flexibility are frequently observed in MDD and provide an important dimension to target with antidepressant treatments [52].”
BackgroundWitt, K., Potts, J., Hubers, A., Grunebaum, M. F., Murrough, J. W., Loo, C., Cipriani, A., & Hawton, K. (2020) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419883341 · Cited by 202 · cited 1×
“In contrast, another systematic review of 25 reports from 15 independent trials (n = 572) found only moderate to low evidence that ketamine had anti-suicidal effects, but the study noted significant heterogeneity in the results and lack of data on actual suicidal behavior [47].”
BackgroundProlonged effect of an anesthetic dose of ketamine on behavioral despair
Yilmaz, A., Schulz, D., Aksoy, A., & Canbeyli, R. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00693-1 · Cited by 199
Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M., Choi, C. J. “., Basaraba, C. N., Pavlicova, M., & Levin, F. R. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18101123 · Cited by 186
Dakwar, E., Levin, F., Hart, C. L., Basaraba, C., Choi, J., Pavlicova, M., & Nunes, E. V. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19070684 · Cited by 183
Ionescu, D. F., Bentley, K. H., Eikermann, M., Taylor, N., Akeju, O., Swee, M. B., Pavone, K. J., Petrie, S. R., Dording, C., Mischoulon, D., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.037 · Cited by 179 · cited 1×
“5 mg/kg over 45 min) administered over the course of three weeks did not outperform placebo [42].”
BackgroundGrabski, M., McAndrew, A., Lawn, W., Marsh, B., Raymen, L., Stevens, T., Hardy, L., Warren, F., Bloomfield, M., Borissova, A., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21030277 · Cited by 175
Convergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171 · cited 1×
“Current evidence suggests that a convergence of multiple pathways may best explain ketamine’s unique therapeutic effects [17] (summarized in Fig.”
BackgroundSelf-citationDwyer, J. B., Landeros-Weisenberger, A., Johnson, J. A., Londono Tobon, A., Flores, J. M., Nasir, M., Couloures, K., Sanacora, G., & Bloch, M. H. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20010018 · Cited by 165
Caddy, C., Giaroli, G., White, T. P., Shergill, S. S., & Tracy, D. K. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313507739 · Cited by 156
Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review
Jones, J. L., Mateus, C. F., Malcolm, R. J., Brady, K. T., & Back, S. E. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00277 · Cited by 153 · cited 1×
“Preliminary data from a small number of completed studies in cocaine, opioid, and alcohol use disorders suggest that ketamine may be useful in treating substance use disorders (reviewed in [60]).”
BackgroundMeta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression
Romeo, B., Choucha, W., Fossati, P., & Rotge, J.-Y. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.10.032 · Cited by 151
Murrough, J. W., Burdick, K. E., Levitch, C. F., Perez, A. M., Brallier, J. W., Chang, L. C., Foulkes, A., Charney, D. S., Mathew, S. J., & Iosifescu, D. V. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.298 · Cited by 142
Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial
Taylor, J. H., Landeros-Weisenberger, A., Coughlin, C., Mulqueen, J., Johnson, J. A., Gabriel, D., Reed, M. O., Jakubovski, E., & Bloch, M. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.194 · Cited by 142 · cited 1×
“The treatment of social anxiety disorder (SAD) with ketamine infusion was studied in a randomized, double-blind, placebo-controlled crossover study (n = 18) [56].”
MethodNovel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
Self-citationSwainson, J., McGirr, A., Blier, P., Brietzke, E. M., Richard‐Devantoy, S., Ravindran, N., Blier, J., Beaulieu, S., Frey, B. N., Kennedy, S. H., et al. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720970860 · Cited by 141
Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons
Zeilhofer, H. U., Swandulla, D., Geißlinger, G., & Brune, K. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90248-3 · Cited by 137
Shiroma, P. R., THURAS, P. D., Wels, J., Albott, C. S., Erbes, C. R., Tye, S. J., & Lim, K. O. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00897-0 · Cited by 135 · cited 1×
“In contrast, another randomized, double-blind, placebo-controlled study of six repeated infusions versus a single IV ketamine infusion in patients with TRD found no significant difference in symptom remission at two weeks [41].”
Garcia, L. S. B., Comim, C. M., Valvassori, S. S., Réus, G. Z., Andreazza, A. C., Stertz, L., Fries, G. R., Gavioli, E. C., Kapczinski, F. P., & Quevedo, J. (2008) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2008.00210.x · Cited by 133
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133 · cited 1×
“, AMPA, mGluR); mediation via opioidergic mechanisms; the interplay between the glutamatergic and GABA-ergic systems; and downstream effects on signal transduction cascades such as mTOR, cellular proliferation, and neuroplasticity cascades [88].”
BackgroundSelf-citationEkstrand, J., Fattah, C., Persson, M., Cheng, T., Nordanskog, P., Åkeson, J., Tingström, A., Lindström, M. B., Nordenskjöld, A., & Movahed Rad, P. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab088 · Cited by 113
Effect of Baseline Anxious Depression on Initial and Sustained Antidepressant Response to Ketamine
Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J., Richards, E. M., Slonena, E. E., Vande Voort, J. L., Brutsche, N. E., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09049 · Cited by 111 · cited 1×
“Preliminary evidence suggests that anxious depression may respond better to ketamine treatment than non-anxious depression [49, 50].”
BackgroundSelf-citationWilkinson, S. T., Rhee, T. G., Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., & Sanacora, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517074 · Cited by 108 · cited 4×
“A recent follow-up study randomized 28 patients who had achieved response after six ketamine infusions to receive either CBT or treatment as usual [67].”
BackgroundInfluentialWitkin, J. M., Monn, J. A., Schoepp, D. D., Li, X., Overshiner, C., Mitchell, S. N., Carter, G., Johnson, B., Rasmussen, K., & Rorick-Kehn, L. M. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233627 · Cited by 105 · cited 1×
“The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor [11], metabotropic glutamate receptor (mGluR) [12, 13], and opioidergic [14] signaling pathways have all been implicated in ketamine’s antidepressant properties.”
BackgroundTreatment of compulsive behaviour in eating disorders with intermittent ketamine infusions
Mills, I. G. (1998) · QJM · doi:10.1093/qjmed/91.7.493 · Cited by 87 · cited 1×
“In one open-label study of 15 patients with chronic and refractory eating disorders, ketamine was infused at 20 mg/hr for 10 h, and patients also received 20 mg of the opioid antagonist nalmefene twice daily [63].”
MethodDomany, Y., Shelton, R. C., & McCullumsmith, C. B. (2020) · Depression and Anxiety · doi:10.1002/da.22975 · Cited by 84 · cited 1×
“2 mg/kg) reduced suicidal ideation [45].”
Nikkheslat, N. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100383 · Cited by 83 · cited 1×
“In addition, a growing literature has implicated the role of inflammation in MDD, and ketamine’s anti-inflammatory properties have thus gained increased consideration as another mechanism potentially underlying its antidepressant effects [15].”
BackgroundFreeman, M. P., Papakostas, G. I., Hoeppner, B. B., Mazzone, E., Judge, H., Cusin, C., Mathew, S. J., Sanacora, G., Iosifescu, D. V., DeBattista, C., et al. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.010 · Cited by 75 · cited 1×
“In addition, both preclinical and clinical studies have demonstrated sex differences in the antidepressant efficacy and side effect profile of ketamine and its metabolites, further underscoring its pharmacokinetic complexity [19, 20].”
BackgroundRemission from Chronic Anorexia Nervosa With Ketogenic Diet and Ketamine: Case Report
Scolnick, B., Zupec‐Kania, B., Calabrese, L. V., Aoki, C. J., & Hildebrandt, T. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00763 · Cited by 73 · cited 1×
“5 mg/kg over 40 min)-assisted psychotherapy [64]; a case report of remission of anorexia nervosa at six months follow-up after a series of titrated IV ketamine infusions (0.”
BackgroundPonton, E., Turecki, G., & Nagy, C. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab082 · Cited by 64 · cited 1×
“In addition, both preclinical and clinical studies have demonstrated sex differences in the antidepressant efficacy and side effect profile of ketamine and its metabolites, further underscoring its pharmacokinetic complexity [19, 20].”
RYBAKOWSKI, J. K., Permoda‐Osip, A., & Bartkowska‐Śniatkowska, A. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1297834 · Cited by 62 · cited 1×
“A subsequent, open-label study of single-dose IV ketamine infusion in 53 individuals with bipolar depression similarly demonstrated that ketamine, used in conjunction with a mood stabilizer, had rapid antidepressant effects [32].”
BackgroundShiroma, P. R., THURAS, P. D., Wels, J., Albott, C. S., Erbes, C. R., Tye, S. J., & Lim, K. O. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.08.058 · Cited by 54 · cited 1×
“In another study of 43 individuals with TRD randomized to receive one or six ketamine infusions, researchers reported some improvements in short-term neurocognitive function, particularly in the domains of processing speed, set shifting, and spatial working memory [54].”
BackgroundSalloum, N. C., D, M. F. M., Freeman, M. P., Flynn, M., Hoeppner, B. B., Hock, R. S., Cusin, C., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., et al. (2018) · Depression and Anxiety · doi:10.1002/da.22875 · Cited by 53 · cited 1×
“Preliminary evidence suggests that anxious depression may respond better to ketamine treatment than non-anxious depression [49, 50].”
BackgroundDevelopment of the Ketamine Side Effect Tool (KSET)
Short, B., Dong, V., Gálvez, V., Vulovic, V., Martin, D. M., Bayes, A. J., Zarate, C. A., Murrough, J. W., McLoughlin, D. M., Riva‐Posse, P., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.120 · Cited by 52 · cited 1×
“Side effects of both ketamine and esketamine can be monitored using a questionnaire such as the Ketamine Side Effect Tool (KSET) [81].”
MethodSelf-citationThe Efficacy of Ketamine in the Palliative Care Setting: A Comprehensive Review of the Literature
Goldman, N., Frankenthaler, M., & Klepacz, L. (2019) · Journal of Palliative Medicine · doi:10.1089/jpm.2018.0627 · Cited by 49 · cited 2×
“Data from 11 open-label studies and one small, randomized, controlled clinical trial suggest that ketamine has robust antidepressant effects in palliative care settings, though its analgesic properties appear limited [62].”
BackgroundKetamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study
Azhari, N., Hu, H., O’Malley, K. Y., Blocker, M. E., Levin, F. R., & Dakwar, E. (2021) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1808982 · Cited by 48
Schwartz, T., Trunko, M. E., Feifel, D., Lopez, E., Peterson, D., Frank, G. K. W., & Kaye, W. (2021) · Clinical Case Reports · doi:10.1002/ccr3.3869 · Cited by 48 · cited 1×
“2 mg/kg over 45 min) [65]; and a case series of four patients with eating disorder and TRD who received IM ketamine injections with varying degrees of improvement in eating disorder symptoms [66].”
BackgroundNeurobiological biomarkers of response to ketamine
Kadriu, B., Ballard, E. D., Henter, I. D., Murata, S., Gerlus, N., & Zarate, C. A. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.05.003 · Cited by 41 · cited 1×
“Despite these challenges, studying the mechanistic processes and biomarkers that underlie ketamine’s unique properties has fundamentally changed our understanding of the pathophysiology of mood disorders [87].”
BackgroundSelf-citationWilkowska, A., Włodarczyk, A., Gałuszko‐Węgielnik, M., Wiglusz, M. S., & Cubała, W. J. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s325000 · Cited by 41 · cited 1×
“Studies of ketamine in bipolar depression found similar self-limited psychotomimetic and dissociative symptoms that warrant close safety and tolerability monitoring [77].”
BackgroundMcIntyre, R. S., Rosenblat, J. D., Rodrigues, N. B., Lipsitz, O., Chen-Li, D. C. J., Lee, J. G., Nasri, F., Subramaniapillai, M., Kratiuk, K., Wang, A., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113993 · Cited by 38 · cited 1×
“Finally, a recent retrospective study of 68 individuals with TRD found that ketamine had pro-cognitive effects, including depression-independent improvements in working memory as measured by the Trail Making Test [55].”
BackgroundRagnhildstveit, A., Jackson, L. K., Cunningham, S. R., Good, L., Tanner, Q., Roughan, M., & Henrie-Barrus, P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.764112 · Cited by 36 · cited 1×
“2 mg/kg over 45 min) [65]; and a case series of four patients with eating disorder and TRD who received IM ketamine injections with varying degrees of improvement in eating disorder symptoms [66].”
BackgroundThe effects of ketamine on typical and atypical depressive symptoms
Park, L. T., Luckenbaugh, D. A., Pennybaker, S. J., Hopkins, M., Henter, I. D., Lener, M. S., Kadriu, B., Ballard, E. D., & Zarate, C. A. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13216 · Cited by 31
Self-citationWłodarczyk, A., Cubała, W. J., Gałuszko‐Węgielnik, M., & Szarmach, J. (2021) · Medicine · doi:10.1097/md.0000000000026769 · Cited by 25 · cited 1×
“However, these dissociative effects have not been found to be necessary for ketamine’s antidepressant effects [78, 79].”
BackgroundBobo, W. V., Riva‐Posse, P., Goes, F. S., & Parikh, S. V. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20190048 · Cited by 14 · cited 1×
“A recent review of the available evidence supporting current strategies for extending and maintaining antidepressant response to ketamine suggested several options, including repeated continued treatments with either IV ketamine, intranasal esketamine, or oral ketamine; gradually decreasing the frequency of maintenanc…”
Background
Research works printed but not linked: 2
- Orhurhu VJ, Vashisht R, Claus LE, Cohen SP. Ketamine toxicity [Updated 2021 Jul 25]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. https://ncbi.nlm.nih.gov/books/NBK541087/. Accessed 25 Jul 2021.
- Rosenbaum SB, Gupta V, Palacios JL. Ketamine. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. https://www.ncbi.nlm.nih.gov/books/NBK470357. Accessed 19 Feb 2021.
Cited by
Ketamine: Mechanisms and Relevance to Treatment of Depression
Kim, J., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-051322-120608 · Cited by 147
Leal, G. C., Souza-Marques, B., Mello, R. P., Bandeira, I. D., Caliman-Fontes, A. T., Carneiro, B. A., Faria-Guimarães, D., Guerreiro-Costa, L. N. F., Jesus-Nunes, A. P., Silva, S. S., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.151 · Cited by 62
Simmatis, L. E. R., Russo, E. E., Geraci, J., Harmsen, I. E., & Samuel, N. (2023) · npj Mental Health Research · doi:10.1038/s44184-023-00038-7 · Cited by 52
“Newer therapies, including psilocybin and ketamine or intranasal esketamine, are among several compounds being evaluated for their ability to treat MDD, particularly in treatment-resistant depression 3 – 5 .”
BackgroundPardossi, S., Fagiolini, A., & Cuomo, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313098 · Cited by 51
“Thus, ketamine impacts neuroplasticity, including through BDNF, in both a rapid and sustained manner [18,19,77] (Figure 3).”
InfluentialApplication of Intranasal Administration in the Delivery of Antidepressant Active Ingredients
Jin, Z., Han, Y., Zhang, D., Li, Z., Jing, Y., Hu, B., & Sun, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102070 · Cited by 48
Metadata
- Authors
- Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Yavi, Mani
- Venue
- Discover Mental Health
- Published
- 2022-04-15
- Volume
- 2
- Issue
- 1
- Pages
- 9-9
- ISSN
- 2731-4383 (ISSN-L)
- PMC
- PMC9010394
- OpenAlex
- W4224044203
- Cited by
- 161
- References
- 87
- Citations by year
- 2026: 30 · 2025: 54 · 2024: 38 · 2023: 31 · 2022: 8
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Discover Mental Health (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (ZIAMH002857)
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, esketamine, major depressive disorder, treatment-resistant depression, bipolar depression, adjunctive antidepressant therapy, risk evaluation and mitigation strategy, suicidality, obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse, social anxiety disorder, hypertension, mood disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.